Investigational immunomodulatory therapies for COVID-19

被引：0

作者：

Assi, M. ^{[1
]}

Koshy, K. M. ^{[2
]}

El Atrouni, W. ^{[3
]}

Burke, K. ^{[4
]}

Berg, M. ^{[4
]}

Opardija, A. ^{[5
]}

Temesgen, Z. ^{[6
]}

机构：

[1] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA USA

[2] Yale New Haven Hlth, Bridgeport Hosp, Bridgeport, CT USA

[3] Univ Kansas, Sch Med, Div Infect Dis, Kansas City, KS USA

[4] Wolters Kluwer, Clin Effectiveness, Indianapolis, IN USA

[5] Univ Calif San Francisco, Div Infect Dis, Fresno, CA USA

[6] Mayo Clin & Mayo Fdn, Div Infect Dis, Rochester, MN USA

来源：

DRUGS OF THE FUTURE | 2021年 / 46卷 / 09期

关键词：

COVID-19; Immunomodulatory therapies; Anti-IL-6; agents; Corticosteroids; Monoclonal antibodies; Anti-IL-1; Janus kinase inhibitors; Interferons; GM-CSF; CCR5; antagonists; CCR2; RESPIRATORY SYNDROME-CORONAVIRUS; ENDOTHELIAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; CHEMOKINE RECEPTOR CCR5; CRITICALLY-ILL PATIENTS; SARS-CORONAVIRUS; DISTRESS-SYNDROME; CYTOKINE STORM; UP-REGULATION; IN-VITRO;

D O I：

10.1358/dof.2021.46.9.3317238

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

A large number of candidate drugs are undergoing evaluation for their potential to modulate the pathologic host immune response to SARS-CoV-2 infection. Clinical trial efficacy and safety data are slowly emerging for several of these agents. We provide a summary of candidate immunomodulatory agents, which are registered in ClinicalTrials.gov , and for which clinical data are available. We provide the rationale for their consideration for the treatment of COVID-19, as well as report on data available from the various clinical investigations of their efficacy and safety.

引用

页码：711 / 729

页数：19

共 160 条

[1] Dysregulation of type I interferon responses in COVID-19 [J].

Acharya, Dhiraj ;

Liu, GuanQun ;

Gack, Michaela U. .

NATURE REVIEWS IMMUNOLOGY, 2020, 20 (07) :397-398

[2] Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 [J].

Ackermann, Maximilian ;

Verleden, Stijn E. ;

Kuehnel, Mark ;

Haverich, Axel ;

Welte, Tobias ;

Laenger, Florian ;

Vanstapel, Arno ;

Werlein, Christopher ;

Stark, Helge ;

Tzankov, Alexandar ;

Li, William W. ;

Li, Vincent W. ;

Mentzer, Steven J. ;

Jonigk, Danny .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (02) :120-128

[3]

Actemra (tocilizumab), PRESCRIBING INFORM

[4] Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) [J].

Agarwal, Anup ;

Mukherjee, Aparna ;

Kumar, Gunjan ;

Chatterjee, Pranab ;

Bhatnagar, Tarun ;

Malhotra, Pankaj .

BMJ-BRITISH MEDICAL JOURNAL, 2020, 371

[5] Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study [J].

Al-Tawfiq, Jaffar A. ;

Momattin, Hisham ;

Dib, Jean ;

Memish, Ziad A. .

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 20 :42-46

[6] CCR5 is a receptor for Staphylococcus aureus leukotoxin ED [J].

Alonzo, Francis, III ;

Kozhaya, Lina ;

Rawlings, Stephen A. ;

Reyes-Robles, Tamara ;

DuMont, Ashley L. ;

Myszka, David G. ;

Landau, Nathaniel R. ;

Unutmaz, Derya ;

Torres, Victor J. .

NATURE, 2013, 493 (7430) :51-+

[7]

[Anonymous], IDSA GUID TREATM MAN

[8]

[Anonymous], COR DIS 2019 COVID 1

[9]

[Anonymous], 2021, COVID 19 CLIN MANAGE

[10]

[Anonymous], 2020, WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020

← 1 2 3 4 5 6 7 8 9 10 →